Skip to main content
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. — Investor Relations & Filings

Ticker · SYRE ISIN · US00773J1034 LEI · 52990017AIJPRH3HQH40 US Manufacturing
Open in API
Filings indexed 740 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country US United States of America
Listing US SYRE

About Spyre Therapeutics, Inc.

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's approach involves engineering novel antibodies with prolonged activity in the body, which allows for less frequent dosing. Its pipeline targets validated biological mechanisms and explores the use of these antibodies as both monotherapies and in rational combination therapies. Spyre aims to provide treatment options for various gastrointestinal and rheumatic diseases that offer the potential for enhanced efficacy and greater convenience.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 90% confidence The document is a U.S. SEC Form 8-K “Current Report” under the Securities Exchange Act of 1934, describing an amendment to a license agreement and listing an attached exhibit. It does not present full financial statements or detailed investor presentations, nor is it announcing dividends, management changes, or share issuances. It is a general regulatory filing under Form 8-K, making it best classified as a Regulatory Filing (RNS).
2026-06-01 English
8-K
Regulatory Filings
2026-05-29 English
8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
Regulatory Filings
2026-05-05 English
10-Q - Spyre Therapeutics, Inc. (0001636282) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-05 English
8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
Regulatory Filings
2026-04-16 English
424B5 - Spyre Therapeutics, Inc. (0001636282) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) under a shelf registration statement (Form S-3). It details an offering of $300 million of common stock, including underwriting details, risk factors, use of proceeds, and other offering-specific information. The document is clearly a capital raising filing related to a securities offering, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual offering document. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, consistent with a prospectus supplement for a capital raise.
2026-04-13 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.